|drug2583||No intervention, observational study Wiki||0.58|
|drug3728||Standard of Care Wiki||0.16|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of this study is to determine if a video visit with an advanced practice provider (Nurse Practitioner or Physician Assistant) within 7 days of discharge from Hospital Internal Medicine services will increase patient compliance with medication, self-management and home supports after hospital discharge.
Description: Number of participants to adhere to post-discharge recommendation including medication compliance, self-management, and home supports post hospital dischargeMeasure: Adherence to post-discharge recommendations Time: Through study completion, approximately 30 days
Description: Number of participants with hospital emergency department visits and hospital readmission within 7 days of dischargeMeasure: 7 day readmission rate Time: 7 days after hospital discharge
Description: Number of participants with hospital emergency department visits and hospital readmission within 30 days of dischargeMeasure: 30 day readmission rate Time: 30 days after hospital discharge
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports